DEMYELINATING DISEASE AFTER EXPOSURE TO TUMOR NECROSIS FACTOR ALPHA INHIBITORS (TNFI): LONG-TERM OUTCOMES FROM A SINGLE CENTER

被引：0
|
作者：
Stienstra, N. [1 ]
Lane, M. [2 ]
Horton, J. [1 ]
Kumthekar, A. [3 ]
Sathe, N. [4 ]
Sunny, C. [1 ]
Yadav, V. [2 ]
Deodhar, A. [1 ]
机构：
[1] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA
[3] Albert Einstein Coll Med, Div Rheumatol, The Bronx, NY USA
[4] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.1631
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0323
引用
收藏
页码：1456 / 1456
页数：1
相关论文
共 50 条
  • [1] Prevalence of paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) in children from a single tertiary center
    Kodama, S.
    Rosenwasser, N.
    Gupta, D.
    Sullivan, E.
    Zhao, Y.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 23 - 23
  • [2] Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
    Kodama, Sarah
    Gupta, Deepti
    Sullivan, Erin
    Zhao, Yongdong
    ARTHRITIS & RHEUMATOLOGY, 2020, 72 : 232 - 233
  • [3] Demyelinating Disease After Exposure to Tumor Necrosis Factor α Inhibitors A Case Series in a Tertiary Care Center
    Stienstra, Nicholas
    Horton, Joel
    Lane, Michael
    Kumthekar, Anand
    Sathe, Nishad
    Sunny, Christy
    Yadav, Vijayshree
    Deodhar, Atul
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2022, 28 (02) : E638 - E641
  • [4] Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
    Kucharz, Eugeniusz Jozef
    Kotulska-Kucharz, Anna
    REUMATOLOGIA, 2021, 59 (02): : 65 - 67
  • [5] Utilization of Tumor Necrosis Factor alpha Inhibitors (TNFi) in Patients with Ankylosing Spondylitis
    He, Jinghua
    Watson, Douglas J.
    Peloso, Paul M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 42 - 42
  • [6] Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup
    Schmidt, Jean
    Kermani, Tanaz A.
    Bacani, A. Kirstin
    Crowson, Cynthia S.
    Matteson, Eric L.
    Warrington, Kenneth J.
    ARTHRITIS CARE & RESEARCH, 2012, 64 (07) : 1079 - 1083
  • [7] Outcomes of Long-term Tumor Necrosis Factor Alpha Inhibitor Therapy Beyond 10 Years in Inflammatory Bowel Disease
    Dicken, Quinten
    Omede, Mmeyeneabasi
    Ananthakrishnan, Ashwin n.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2025, 23 (04)
  • [8] Induced myelopathy after long-term anti-tumor necrosis factor alpha treatment
    C Modesto
    F Caracsegui
    S Melendo
    A Sanchez-Montanez
    Manel Roig
    Pediatric Rheumatology, 9 (Suppl 1)
  • [9] Tumor Necrosis Factor Inhibitors in Patients with Takayasu Arteritis: Experience From a Referral Center with Long-Term Follow-up
    Schmidt, Jean
    Kermani, Tanaz A.
    Bacani, A. Kirstin
    Crowson, Cynthia S.
    Matteson, Eric L.
    Warrington, Kenneth J.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S587 - S587
  • [10] Long-Term Outcomes With Teduglutide From a Single Center
    Puello, Frances
    Wall, Elizabeth
    Herlitz, Jean
    Lozano, Edward S.
    Semrad, Carol
    Micic, Dejan
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2021, 45 (02) : 318 - 322
12345